Phase 2 N=159 Study of GTx-024 on Muscle Wasting (Cachexia) Cancer.
Cachexia
Primary: The Efficacy of GTx-024 on Total Body Lean Mass. — 1.55; 0.98; 0.02 kg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=11 Study to Assess the Safety and Tolerability of Repeated Doses of an Investigational New Drug in Patients With Cancer and Cachexia.
Cachexia · Non-Small-Cell Lung Cancer · Pancreatic Cancer
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 10; 4 Participants
N/A N=539 Non-interventional Study to Assess the Frequency of Cachexia in Patients With Non-small Cell Lung Cancer.
Non-small Cell Lung Cancer · Cachexia
Primary: Frequency of Cachexia According to Modified Fearon Criteria — 173 Participants
Phase 2 N=227 SUN11031 in Cachexia Associated With Chronic Obstructive Pulmonary Disease (COPD)
Cachexia
Primary: Mean Change From Baseline to Day 85 in the Distance Walked During the 6 Minute Walk Test (MWT) Following Treatment With SUN11031 in Participants Having Cachexia…
Phase 2 N=15 Pilot Clinical Trial of Repeated Doses of Macimorelin to Assess Safety and Efficacy in Patients With Cancer Cachexia
Cancer Cachexia
Primary: Change of Body Weight — 0; 0.2 kg
Phase 2 N=37 Regimen for the Treatment of Cachexia in Subjects With NSCLC
Cachexia
Primary: Proportion of Subjects With a Positive Change From Baseline to Week 4 in Lean Body Mass — 8; 6; 5; 3 participants
Phase 1 N=24 Testosterone for Treating Cachexia in Patients With Squamous Cell Carcinoma
Cachexia · Squamous Cell Carcinoma
Primary: Change in Total Lean Body Mass as Measured by Dual Energy X-ray Absorptiometry (DEXA) From Baseline to 7 Weeks. — -3.31; 1.42 Percent change
Phase 2 N=67 BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia
Chronic Obstructive Pulmonary Disease (COPD) With Cachexia
Primary: Percentage Change From Baseline of Thigh Muscle Volume (TMV) by MRI Scan at Week 4, 8, 16, and 24 — 5.87; 0.02; 7.01; -0.65 Percentage Change of TMV — p=<0.001
N/A N=36 A Pilot Study of Eicosapentaenoic Acid (EPA) in Patients With Cancer Cachexia
Cancer Cachexia
Primary: Change in Serum Albumin — 4.0 g/dL
Phase 3 N=513 Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
Cachexia · Non-Small Cell Lung Cancer
Primary: Percentage of Participants With Treatment-emergent Adverse Events — 52; 56 percentage of participants
Phase 2 N=187 Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15
Non-small Cell Lung Cancer · Pancreatic Cancer · Colorectal Cancer
Primary: Part A: Change From Baseline in Body Weight at Week 12 — NA; NA; NA; NA Kilogram
Phase 3 N=484 Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1)
Cachexia · Non-Small Cell Lung Cancer
Primary: Change in Lean Body Mass — 0.99; -0.47 kg — p=< 0.0001
Phase 3 N=495 Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2)
Cachexia · Non-Small Cell Lung Cancer
Primary: Change in Lean Body Mass — 0.65; -0.98 kg — p=< 0.0001
N/A N=15 Cancer Anorexia and the Central Nervous System
Cancer Cachexia
Primary: ACTIVATION/NON ACTIVATION OF SPECIFIC BRAIN AREAS, EVALUATED BY FUNCTIONAL MAGNETIC RESONANCE — 585.57; 667.92; 511.22 BOLD
Phase 2 N=5 Ghrelin Dose Finding In Frail Elderly
The Frailty Syndrome
Primary: Treatment Emergent Adverse Events — 1; 0; 1; 0 Events
Phase 2 N=57 Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas
Cachexia
Primary: Percentage Change From Baseline of Thigh Muscle Volume (TMV) by MRI Scan at Week 8 — 2.0; 0.65 Percentage Change of TMV
Phase 2 N=5 Ghrelin Repeated Dose Study
Frailty in Aging
Primary: Safety — 4 participants
N/A N=469 Prognostic Value of Sarcopenia and Nutritional Status in Early-stage Non-small Cell Lung Cancer
Sarcopenia · Non Small Cell Lung Cancer · Malnutrition
Primary: Progression Free Survival (PFS) — 350; 773 days
Phase 2 N=16 Ghrelin Plus Strength Training in Frail Elderly Study
Frailty Syndrome
Primary: Change in the Short Physical Performance Battery (SPPB) — 0.6; 2.4 units on a scale
Phase 3 N=318 A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Cachexia; Cancer · Non Small Cell Lung Cancer
Primary: Mean Change From Baseline in Body Weight Over 12 Weeks — 1.938; 0.594 Change from baseline in body weight (kg) — p=<0.0001
Phase 3 N=318 A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Cachexia; Cancer · Non Small Cell Lung Cancer
Primary: Mean Change From Baseline in Body Weight Over 12 Weeks — 1.822; 0.538 kg — p=<0.0001
N/A N=40 Assessment of Body Composition and Physical Function
Body Composition · Physical Function
Primary: Fat Mass — 44.71 Kg
N/A N=30 Nutritional Biomarkers of Sarcopenia
Sarcopenia
Primary: Resting and Maximum Plasma Leucine Concentration — 659; 755; 721; 95 micromoles per liter
Phase 3 N=321 Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)
Muscle Wasting · Non Small Cell Lung Cancer
Primary: Physical Function — 29.4; 24.2 percentage of subjects
N/A N=16 Effect of an EAA/Whey Composition on Protein Metabolism
Sarcopenia
Primary: Protein Anabolism — 3.56; 11.8; 3.02 grams — p=<0.05
Phase 2 N=170 A Study of the Safety and Efficacy of MK-0773 in Women With Sarcopenia (Loss of Muscle Mass)(MK-0773-005)
Sarcopenia
Primary: Change From Baseline in Participant Lean Body Mass — 1.26; 0.29 kg
N/A N=25 Androgen Effects in HIV-infected Women
HIV Infection
Primary: Lean Body Mass — 1.8; 0.8 kilograms — p=0.04
Phase 3 N=73 Melatonin Versus Placebo and the Effect on Appetite in Advanced Cancer Patients
Gastrointestinal Cancer · Lung Cancer
Primary: Change in Appetite as Measured by ESAS — -0.83; -1.19 units on a scale
Phase 2 N=23 Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer
Locally Advanced Unresectable Pancreatic Adenocarcinoma · Metastatic Pancreatic Adenocarcinoma · Recurrent Pancreatic Adenocarcinoma
Primary: Weight Stability — -1.98; -5.58 Percent weight change
N/A N=37 Exercise to Prevent Muscle Mass and Functional Loss in Elderly Dialysis Patients
Chronic Kidney Disease
Primary: Maximal Oxygen Uptake — 14.5; 15.1 ml/kg/min